Hartmut Dohner
MD
Professor and Chairman, Department of Internal Medicine III
👥Biography 个人简介
Hartmut Dohner is the principal architect of the European LeukemiaNet (ELN) AML risk stratification guidelines, which are used worldwide to guide treatment decisions. His research has defined the prognostic significance of cytogenetic and molecular abnormalities in AML. He led the pivotal RATIFY trial demonstrating benefit of midostaurin in FLT3-mutated AML. He remains a leading voice in international AML classification and management.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Hartmut Dohner 的研究动态
Follow Hartmut Dohner's research updates
留下邮箱，当我们发布与 Hartmut Dohner（Ulm University Hospital）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment